Human papillomavirus vaccine initiation among 9–13-year-olds in the United States

The quadrivalent and 9-valent human papillomavirus (HPV) vaccines are licensed for administration among 9–26-year-old males and females, with routine vaccination recommended for 11–12-year-olds. Despite the availability of the vaccine at younger ages, few studies have explored vaccine uptake prior t...

Full description

Bibliographic Details
Main Authors: Kelly L. Donahue, Kristin S. Hendrix, Lynne A. Sturm, Gregory D. Zimet
Format: Article
Language:English
Published: Elsevier 2015-01-01
Series:Preventive Medicine Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S221133551500145X
_version_ 1818249497791168512
author Kelly L. Donahue
Kristin S. Hendrix
Lynne A. Sturm
Gregory D. Zimet
author_facet Kelly L. Donahue
Kristin S. Hendrix
Lynne A. Sturm
Gregory D. Zimet
author_sort Kelly L. Donahue
collection DOAJ
description The quadrivalent and 9-valent human papillomavirus (HPV) vaccines are licensed for administration among 9–26-year-old males and females, with routine vaccination recommended for 11–12-year-olds. Despite the availability of the vaccine at younger ages, few studies have explored vaccine uptake prior to age 13, and national HPV vaccination surveillance data is limited to 13–17-year-olds. Our objective was to examine rates and predictors of HPV vaccine initiation among 9–13-year-olds in the United States. A national sample of mothers of 9–13-year-olds in the United States (N = 2446) completed a 2014 Web-based survey assessing socio-demographic characteristics, child's HPV vaccination history, provider communication regarding the vaccine, and other attitudes and behaviors pertaining to vaccination and healthcare utilization. The main outcome measure was child's initiation of the HPV vaccine (i.e., receipt of one or more doses). Approximately 35% of the full sample and 27.5% of the 9–10-year-olds had initiated HPV vaccination. Females were more likely than males to have initiated HPV vaccination by the age of 13 but not by younger ages. Strength of health provider recommendation regarding HPV vaccination was a particularly salient predictor of vaccine initiation. Approximately a third of children may be initiating the HPV vaccine series before or during the targeted age range for routine administration of the vaccine. Because coverage remains below national targets, further research aimed at increasing vaccination during early adolescence is needed. Improving providers' communication with parents about the HPV vaccine may be one potential mechanism for increasing vaccine coverage.
first_indexed 2024-12-12T15:37:26Z
format Article
id doaj.art-6bd6fd58b6b24ea3adac60583bb98462
institution Directory Open Access Journal
issn 2211-3355
language English
last_indexed 2024-12-12T15:37:26Z
publishDate 2015-01-01
publisher Elsevier
record_format Article
series Preventive Medicine Reports
spelling doaj.art-6bd6fd58b6b24ea3adac60583bb984622022-12-22T00:19:59ZengElsevierPreventive Medicine Reports2211-33552015-01-012C89289810.1016/j.pmedr.2015.10.003Human papillomavirus vaccine initiation among 9–13-year-olds in the United StatesKelly L. DonahueKristin S. HendrixLynne A. SturmGregory D. ZimetThe quadrivalent and 9-valent human papillomavirus (HPV) vaccines are licensed for administration among 9–26-year-old males and females, with routine vaccination recommended for 11–12-year-olds. Despite the availability of the vaccine at younger ages, few studies have explored vaccine uptake prior to age 13, and national HPV vaccination surveillance data is limited to 13–17-year-olds. Our objective was to examine rates and predictors of HPV vaccine initiation among 9–13-year-olds in the United States. A national sample of mothers of 9–13-year-olds in the United States (N = 2446) completed a 2014 Web-based survey assessing socio-demographic characteristics, child's HPV vaccination history, provider communication regarding the vaccine, and other attitudes and behaviors pertaining to vaccination and healthcare utilization. The main outcome measure was child's initiation of the HPV vaccine (i.e., receipt of one or more doses). Approximately 35% of the full sample and 27.5% of the 9–10-year-olds had initiated HPV vaccination. Females were more likely than males to have initiated HPV vaccination by the age of 13 but not by younger ages. Strength of health provider recommendation regarding HPV vaccination was a particularly salient predictor of vaccine initiation. Approximately a third of children may be initiating the HPV vaccine series before or during the targeted age range for routine administration of the vaccine. Because coverage remains below national targets, further research aimed at increasing vaccination during early adolescence is needed. Improving providers' communication with parents about the HPV vaccine may be one potential mechanism for increasing vaccine coverage.http://www.sciencedirect.com/science/article/pii/S221133551500145XEarly adolescenceHealthcare providersImmunization
spellingShingle Kelly L. Donahue
Kristin S. Hendrix
Lynne A. Sturm
Gregory D. Zimet
Human papillomavirus vaccine initiation among 9–13-year-olds in the United States
Preventive Medicine Reports
Early adolescence
Healthcare providers
Immunization
title Human papillomavirus vaccine initiation among 9–13-year-olds in the United States
title_full Human papillomavirus vaccine initiation among 9–13-year-olds in the United States
title_fullStr Human papillomavirus vaccine initiation among 9–13-year-olds in the United States
title_full_unstemmed Human papillomavirus vaccine initiation among 9–13-year-olds in the United States
title_short Human papillomavirus vaccine initiation among 9–13-year-olds in the United States
title_sort human papillomavirus vaccine initiation among 9 13 year olds in the united states
topic Early adolescence
Healthcare providers
Immunization
url http://www.sciencedirect.com/science/article/pii/S221133551500145X
work_keys_str_mv AT kellyldonahue humanpapillomavirusvaccineinitiationamong913yearoldsintheunitedstates
AT kristinshendrix humanpapillomavirusvaccineinitiationamong913yearoldsintheunitedstates
AT lynneasturm humanpapillomavirusvaccineinitiationamong913yearoldsintheunitedstates
AT gregorydzimet humanpapillomavirusvaccineinitiationamong913yearoldsintheunitedstates